Cargando…
Thiazolidinediones and Cardiovascular Risk — A Question of Balance
BACKGROUND: Several recent meta-analyses of adverse event data from randomized controlled trials with rosiglitazone reveal a possible association between this thiazolidinedione and an increased risk of ischemic myocardial events. This has led to debate on the overall clinical benefit of glitazone th...
Autores principales: | Erdmann, Erland, Charbonnel, Bernard, Wilcox, Robert |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822138/ https://www.ncbi.nlm.nih.gov/pubmed/20676274 http://dx.doi.org/10.2174/157340309788970333 |
Ejemplares similares
-
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study
por: Erdmann, Erland, et al.
Publicado: (2007) -
Risk of Fracture with Thiazolidinediones: Disease or Drugs?
por: Bazelier, Marloes T., et al.
Publicado: (2012) -
Chemotherapy and Chemoprevention by Thiazolidinediones
por: Fröhlich, Eleonore, et al.
Publicado: (2015) -
Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention
por: Horita, Shoko, et al.
Publicado: (2015) -
Thiazolidinediones and bone fractures
por: Kaku, Kohei, et al.
Publicado: (2011)